Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab
Several ASAS HI improvement thresholds discriminated axSpA patients in treatment vs. placebo arms at Week 16. The ASAS HI ≥30% improvement threshold discriminated across all three COAST trials.
Authors
- Uta Kiltz (ORCID: https://orcid.org/0000-0001-5668-4497)
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Khai Jing Ng (ORCID: https://orcid.org/0000-0003-1486-6270)
- Annelies Boonen (ORCID: https://orcid.org/0000-0003-0682-9533)
- Christophe Sapin (ORCID: https://orcid.org/0000-0001-7655-7129)
- Anna Moltó (ORCID: https://orcid.org/0000-0003-2246-1986)
- Andris Kronbergs
- Louis Bessette (ORCID: https://orcid.org/0000-0002-6834-2731)
- Rebecca Bolce
- Jürgen Braun
- Désirée van der Heijde
- Boris Janos
Institutions
- Inserm (FR)
- Eli Lilly (United States) (US)
- Université Paris Cité (FR)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Rheumazentrum Ruhrgebiet (DE)
- Hôpital Cochin (FR)
- Université Laval (CA)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Seminars in Arthritis and Rheumatism
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1016/j.semarthrit.2025.152777
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company